Tema Oncology ETF (NASDAQ:CANC) Short Interest Down 18.2% in March

Tema Oncology ETF (NASDAQ:CANC) was the recipient of a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 1,800 shares, a drop of 18.2% from the March 15th total of 2,200 shares. Based on an average daily volume of 17,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the company’s shares are short sold.

Tema Oncology ETF Trading Up 1.8 %

NASDAQ:CANC traded up $0.41 on Tuesday, reaching $23.61. 491 shares of the stock traded hands, compared to its average volume of 11,867. Tema Oncology ETF has a 1-year low of $20.10 and a 1-year high of $30.11. The company’s 50 day moving average is $24.29 and its 200-day moving average is $25.65. The firm has a market capitalization of $63.52 million, a price-to-earnings ratio of 20.79 and a beta of 1.11.

Hedge Funds Weigh In On Tema Oncology ETF

An institutional investor recently raised its position in Tema Oncology ETF stock. Thrivent Financial for Lutherans increased its position in Tema Oncology ETF (NASDAQ:CANC) by 29.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 517,837 shares of the company’s stock after purchasing an additional 118,328 shares during the period. Thrivent Financial for Lutherans owned approximately 20.31% of Tema Oncology ETF worth $13,156,000 at the end of the most recent quarter.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.